Sleep Cycle (Q3 Initial take): Sales and EBIT in line - Redeye

Redeye comments on Sleep Cycle’s Q3 report, which was in line with expectations. Subscriber growth remained soft due to app store weakness, while partnerships continued to expand. Profitability was strong, with a 27% EBIT margin. Business momentum remains solid, supported by the launch of the Sleep SDK and progress in the sleep apnea initiative. We expect only minor estimate revisions.

Länk till analysen i sin helhet: https://www.redeye.se/research/1131101/sleep-cycle-q3-initial-take-sales-and-ebit-in-line?utm_source=finwire&utm_medium=RSS